O-188 Encouraging activity and durable responses demonstrated by the epithelial growth factor receptor-tyrosine kinase inhibitor, Erlotinib (Tarceva TM, OSI774), in patients with advanced bronchioloalveolar (BAC) cell carcinoma
- 31 August 2003
- journal article
- abstracts
- Published by Elsevier in Lung Cancer
- Vol. 41, S56
- https://doi.org/10.1016/s0169-5002(03)91846-0
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: